Table 6. mAbs competed by human sera as determined by the mAb-CE.
| mAb-CE (% competition ± SD) | B Virus or HSV Status | ||||||
|---|---|---|---|---|---|---|---|
| HUMAN SERA |
12F5.C1 mAb |
12G9.G5 mAb |
7H1.G5 mAb |
B virus | HSV-1 | HSV-2 | ELISA Titer (EU) |
| Hu Neg (Pool) | 2.2±16 | 15.2±30 | -13.2±9.2 | N | N | N | N |
| Hu Neg (VM) | 8.6±8.6 | 13.9±8.9 | 12.8±3.6 | N | N | N | N |
| Hu BV-Pos + VM | 90.9±1.8 | 61.9±0.4 | 95.6±0.2 | NT | NT | NT | NT |
| Hu BV-Pos + anti-HSV1 | 91.0±0.1 | 66.4±4.4 | 92.0±0.1 | NT | NT | NT | NT |
| Hu BV-Pos + anti-HSV2 | 92.3±0.3 | 59.4±1.3 | 90.8±0.6 | NT | NT | NT | NT |
| anti-HSV1 (Pool) | -19.6 | 0.5 | 91.8 | N | P | N | 10,000 |
| anti-HSV2 (Pool) | -30.5 | -14.9 | 86.9 | N | N | P | 3,500 |
| hI (aS) | 15.1±0.2 | 9.0±8.4 | 17.9±0.5 | P | P | N | 2,000 |
| hB (aS) | 25.5±4.4 | 13.0 | 30.9±8.3 | P | N | N | 10,000 |
| hN (aS) | -86.9 | NT | 77.2 | P | P | N | NT |
| hL (aS) | 16.14 | 2.86 | 36.67 | Ind | N | N | 25,000 |
| hO (aS) | 2.4 | -0.3 | 87.7 | P | P | P | 10,000 |
| hP (aS) | 5.6 | -3.7 | 96.7 | N | P | P | 10,000 |
| hR (aS) | 19.0±5.8 | -5.0±32.0 | 98.0±0.4 | P | P | N | 30,000 |
| hS (aS) | 27.0±12.8 | 8.0±30.6 | 51.0±0.8 | P | N | P | 900 |
| hK (aS) | 20.3 | 33.0 | 54.5 | Ind | P | N | 60 |
| hT (aS) | 1.5 | 21.3 | 100.0 | P | N | N | 80,000 |
| hM (aS) | 8.27 | 11.88 | 73.05 | Ind | Ind | Ind | 100 |
| hJ (aS) | -102.3 | NT | 30.9 | P | Ind | Ind | 50 |
| hA (Sy) | 89.8±3.7 | 79.2±3.7 | 89.5±8.1 | P | N | N | 3,000 |
| hG (Sy) | 55.8±0.8 | 52.5±8.2 | 95.4±3.1 | P | N | N | 2,000 |
| hC (Sy) | -41.4 | 14.0 | -37.9 | P | N | N | 250 |
| hF (Sy †) | -67.5 | -52.9 | 43.1 | P | N | N | 250 |
| hH (Sy †) | -47.7 | NT | -28.7 | P | N | N | 600 |
| hD (Sy †) | -47.7 | NT | 60.3 | P | P | N | NT |
| hE (Sy †) | -53.1 | -52.1 | 97.2 | P | P | N | 30,000 |
| hU | 4.2 | NT | -3.3 | N | N | N | N |
| hW | -68.5 | NT | -19.1 | N | N | N | N |
Human sera were competed against the two Category-I mAbs (12F5.C1 and 12G9.G5) and against one Category-III mAb (7H1.G5). Numbers indicate percent competition values. For the sake of the discussion, competition values of 30% or higher were considered as positive (bold numbers). Standard-deviation values (±SD) were calculated from replicate measures. Controls consisted of a pool of herpes virus-negative human sera (Hu Neg (Pool)), a serum sample from a herpes virus-negative individual (Hu Neg (VM)), an anti- HSV-1 positive serum pool (anti-HSV-1 (Pool)), an anti-HSV-2 positive serum pool (anti-HSV-2) (Pool)) and a human B virus positive serum (BV-Pos) spiked with the anti-HSV1 and anti-HSV2 pools diluted to contain 1000 EU of antibodies quantified using ELISA. Some of the control results are identical to the results in Table 4 and were placed here for the sake of comparison.
N, negative; P, positive; Ind, indeterminate; NT, not tested;, aS, asymptomatic; Sy, symptomatic
†, deceased.